SEC Form 4 · accession 0001358403-15-000057
BELLICUM PHARMACEUTICALS, INC · BLCM
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Kevin M. Slawin
Officer — Chief Technology Officer · Director
Period of report
Jul 15, 2015
Accepted (ET)
Jul 17, 2015 · 4:59 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001358403
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Jul 15, 2015 | S | 1,500 | $20.00 | D | 163,008 | D | |
| Common StockF3 | Jul 15, 2015 | S | 3,500 | $20.00 | D | 458,981 | I | By the Jordana Slawin 2012 Family Trust |
| Common StockF4 | Jul 15, 2015 | S | 1,000 | $20.00 | D | 402,066 | I | By the Kevin Slawin 2009 Family Trust |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Reporting Person on March 24, 2015.
- F2The total amount of shares shown in Column 5 on Table I includes one share omitted from the prior reports due to the rounding error.
- F3The Reporting Person's spouse is trustee of the Jordana Slawin 2012 Family Trust. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
- F4The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.